1. 60PResponse rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials. (17th December 2018) Authors: Gogas, H; Gutzmer, R; Malvehy, J; Mehnert, J M; Liu, K; Pickett, C A; Snyder, W; Chesney, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗